Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

American Society of Hematology Annual Meeting

File size: 366.62 KB
Created: December 2022
Updated: October 2024
Hits: 32
Download Preview
Scroll to Top
Scroll to Top